A Phase I Study of NS-079 in Healthy Participants

NCT07669571 | Not Yet Recruiting Phase 1

• 1 other identifier: NS079HV101
• Study Type: interventional
• Target: 78
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is evaluate the safety, pharmacokinetics, and pharmacodynamics of NS-079 with its main metabolite (NS-079-M1) in healthy participants. The main questions it aims to answer are:

• Is NS-079 safe and tolerable in heathy participants under tested dosing regimen?
• What is the pharmacokinectic profile of NS-079 in healthy participants under tested dosing regimen and the effect of paroxetine? Researchers will compare NS-079 to a placebo to see the safety and tolerability when use NS-079.

Conditions

Healthy Adult Participants

Keywords

5-HT2A receptor

Outcome Measures

Primary Outcomes (23)

• Number of Participants with Treatment-Related Adverse Events

  for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

• Main pharmacokinetic parameters

  Cmax

  for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

• Main pharmacokinetic parameters

  Cmax,ss

  for MAD, day 1-14

• Main pharmacokinetic parameters

  NS-079-M1/NS-079 AUC ratio as an in vivo CYP2D6 fm biomarker

  For DDI, Day 1- 30

• Main urine pharmacokinetic parameters

  Ae

  For SAD, Day 1-4; for DDI, day 1-30

• Main pharmacokinetic parameters

  NS-079-M1/NS-079 Ae ratio

  For DDI, day 1-30

• Main pharmacokinetic parameters

  AUC0-∞

  for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

• Main pharmacokinetic parameters

  AUC0-t

  for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

• Main pharmacokinetic parameters

  Tmax

  for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

• Main pharmacokinetic parameters

  t1/2

  for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

• Main pharmacokinetic parameters

  CL/F

  for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

• Main pharmacokinetic parameters

  Vd/F

  for SAD, day 1-4; for MAD, day 1-14, for DDI, day1-30

• Main pharmacokinetic parameters

  Cmin,ss

  for MAD, day 1-14

• Main pharmacokinetic parameters

  Tmax,ss

  for MAD, day 1-14

• Main pharmacokinetic parameters

  Cavg,ss

  for MAD, day 1-14

• Main pharmacokinetic parameters

  AUCss,0-tau

  for MAD, day 1-14

• Main pharmacokinetic parameters

  AUCss,0-∞

  for MAD, day 1-14

• Main pharmacokinetic parameters

  CLss/F

  for MAD, day 1-14

• Main pharmacokinetic parameters

  accumulation factor (Rac)

  for MAD, day 1-14

• Main pharmacokinetic parameters

  DF

  for MAD, day 1-14

• Main urine pharmacokinetic parameters

  Ae%

  For SAD, Day 1-4; for DDI, day 1-30

• Main urine pharmacokinetic parameters

  CLr

  For SAD, Day 1-4; for DDI, day 1-30

• Main urine pharmacokinetic parameters

  ER

  For SAD, Day 1-4; for DDI, day 1-30

Study Arms (17)

NS-079 Arm 1

EXPERIMENTAL

NS-079 SAD Dose 1

Drug: NS-079 tablet

NS-079 Arm 2

EXPERIMENTAL

NS-079 SAD Dose 2

Drug: NS-079 tablet

NS-079 Arm 3

EXPERIMENTAL

NS-079 SAD Dose 3

Drug: NS-079 tablet

NS-079 Arm 4

EXPERIMENTAL

NS-079 SAD Dose 4

Drug: NS-079 tablet

NS-079 Arm 5

EXPERIMENTAL

NS-079 SAD Dose 5

Drug: NS-079 tablet

NS-079 Arm 6

EXPERIMENTAL

NS-079 MAD Dose 1

Drug: NS-079 tablet

NS-079 Arm 7

EXPERIMENTAL

NS-079 MAD Dose 2

Drug: NS-079 tablet

NS-079 Arm 8

EXPERIMENTAL

NS-079 MAD Dose 3

Drug: NS-079 tablet

Placebo Arm 9

PLACEBO COMPARATOR

NS-079 SAD Dose 1 PBO

Drug: Placebo

Placebo Arm 10

PLACEBO COMPARATOR

NS-079 SAD Dose 2 PBO

Drug: Placebo

Placebo Arm 11

PLACEBO COMPARATOR

NS-079 SAD Dose 3 PBO

Drug: Placebo

Placebo Arm 12

PLACEBO COMPARATOR

NS-079 SAD Dose 4 PBO

Drug: Placebo

Placebo Arm 13

PLACEBO COMPARATOR

NS-079 SAD Dose 5 PBO

Drug: Placebo

Placebo Arm 14

PLACEBO COMPARATOR

NS-079 MAD Dose 1 PBO

Drug: Placebo

Placebo Arm 15

PLACEBO COMPARATOR

NS-079 MAD Dose 2 PBO

Drug: Placebo

Placebo Arm 16

PLACEBO COMPARATOR

NS-079 MAD Dose 3 PBO

Drug: Placebo

NS-079 Arm 17

EXPERIMENTAL

NS-079 DDI dose 1

Drug: NS-079 tablet; Drug: Paroxetine

Interventions

Placebo DRUG

NS-079 matching placebo

Placebo Arm 10; Placebo Arm 11; Placebo Arm 12; Placebo Arm 13; Placebo Arm 14; Placebo Arm 15; Placebo Arm 16; Placebo Arm 9

Paroxetine DRUG

DDI study treatment drug

NS-079 Arm 17

NS-079 tablet DRUG

Investigational product NS-079

NS-079 Arm 1; NS-079 Arm 17; NS-079 Arm 2; NS-079 Arm 3; NS-079 Arm 4; NS-079 Arm 5; NS-079 Arm 6; NS-079 Arm 7; NS-079 Arm 8

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy males or females aged 18-55 years (inclusive), with a body mass index (BMI) between 18.00 and 32.00 kg/m2(inclusive) at screening.
• Not participated in any other clinical trials and received an investigational drug or device within the past 30 days or 5 half-lives prior to screening, whichever is longer.
• Women of non-childbearing potential (WONCBP) (as defined in Appendix 1); women of childbearing potential (WOCBP) who are abstinent from heterosexual intercourse as a preferred and usual lifestyle choice, or who agree to use highly effective contraception (as defined in Appendix 1) in combination with a condom from the time of signing the informed consent form until at least 90 days after the last dose of investigational product, agree to refrain from ova donation during this period, and return a negative pregnancy test at screening and baseline (Day -1).
• Surgically sterile males (with verbal confirmation of the absence of sperm in the ejaculate); males who are abstinent from heterosexual intercourse as a preferred and usual lifestyle choice, or who agree to use highly effective contraception with a female partner (as defined in Appendix 1) in combination with a condom from the time of signing the informed consent form until at least 90 days after the last dose of investigational product, and agree to refrain from sperm donation during this period.
• In good health, determined by the investigator/delegate on the basis of medical history, physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratory tests (hematology, coagulation, urinalysis, blood biochemistry). Repeated examination is allowed once per timepoint at the investigator/delegate's discretion.
• Full understanding of the purpose, nature, procedures of the study, and the potential adverse reactions. Participant voluntarily participates and signs the informed consent form before any study procedures begin.
• Agree to provide a biological sample (blood or saliva/buccal swab, per site capability) for Cytochrome P450 2D6 (CYP2D6) pharmacogenetic genotyping during the screening period, and the genotyping results must be available prior to randomization and dosing.
• Participants must be confirmed CYP2D6 Normal Metabolizers (NM) or Intermediate Metabolizers (IM) based on pharmacogenetic genotyping. For Part 3 \[DDI\] participants only: Must have a confirmed CYP2D6 NM status based on pharmacogenetic genotyping.

You may not qualify if:

• Known hypersensitivity or allergy to the investigational product, its excipients, or any of its components, or a history of clinically significant allergic reactions that, in the opinion of the investigator/delegate, may place the participant at increased risk.
• Known hypersensitivity to or severe intolerance of paroxetine or any SSRI (including serotonin syndrome or discontinuation syndrome) (for Part 3 \[DDI\] only).
• Unable to refrain from all known CYP2D6 substrate medications (including over-the-counter (OTC) medications such as dextromethorphan-containing cough and cold preparations) during paroxetine dosing (for Part 3 \[DDI\] only). Final clinical judgment on individual concomitant medications remains with the investigator/delegate.
• Individuals with a history of intolerance to venipuncture or venous catheterization (e.g., recurrent syncope during blood draws or significant needle phobia) that, in the opinion of the investigator/delegate, may interfere with the study procedures.
• Positive serologic test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (Anti-HCV) or human immunodeficiency virus antibody (Anti-HIV) at Screening.
• Average daily smoking of more than 5 cigarettes per day in the 3 months prior to Screening, or inability or unwillingness to abstain from the use of tobacco or nicotine-containing products (including cigarettes, e-cigarettes, vaping products, and nicotine replacement products) from 48 hours prior to the first dose through completion of the final safety follow-up visit.
• Excessive alcohol consumption, defined as average weekly alcohol intake exceeding 14 units during the 4 weeks prior to Screening (1 unit ≈10 g of pure alcohol; 1 alcohol unit is equal to 375ml 3.5% beer, 100 mL of wine, or 30 mL of 40% spirit), unwillingness or inability to abstain from alcohol and alcohol-containing products from 48 hours prior to the first dose through the completion of the final safety follow-up visit, or a positive alcohol breath test at Screening or upon admission to the clinical unit. (A repeat test may be performed once per timepoint at the investigator/delegate's discretion).
• Excessive consumption of caffeinated beverages (e.g., coffee, tea, energy drinks), defined as an average of \>8 cups/day (1 cup ≈ 250 mL) within 3 months prior to screening, or unwillingness or inability to refrain from caffeinated beverages from 48 hours prior to the first dose through the end of the inpatient confinement phase.
• Unwillingness or inability to abstain from grapefruit or grapefruit containing products, Seville (bitter) oranges, or pomelo/pomelo-containing products from 7 days prior to the first dose through the end of the inpatient confinement phase.
• Use of classic psychedelics or hallucinogenic substances with primary 5-HT2A agonist activity (e.g., lysergic acid diethylamide \[LSD\], psilocybin/magic mushrooms, dimethyltryptamine \[DMT\], ayahuasca, mescaline) on 5 or more occasions lifetime, or any use within 5 years prior to Screening.
• Current or past substance use disorder (including alcohol or drugs of abuse) within the 12 months prior to Screening, as judged by the investigator/delegate; use of ketamine or phencyclidine (PCP) for recreational or non-prescribed purposes within 12 months prior to Screening; use of cannabis within 6 weeks prior to Screening; use of other illicit drugs or non-prescribed psychoactive substances (including but not limited to MDMA, cocaine, opiates, amphetamines) within 4 weeks prior to Screening; or a positive drug of abuse urine screen at Screening or upon admission. Single or occasional use prior to the applicable washout period may be permitted at the investigator/delegate's discretion, provided the urine drug screen is negative. A repeat drug screen may be performed once per timepoint at the investigator/delegate's discretion.
• History or presence of the following conditions:
• Clinically significant (as judged by the investigator/delegate) neurological or psychiatric disorders, defined as any of the following: history of epilepsy or any seizure disorder (excluding childhood febrile seizures); history of dementia or any clinically diagnosed cognitive disorder; clinically significant migraine, defined as: history of migraine with aura; chronic migraine (≥4 migraine days/month on average over the past 6 months); or use of prophylactic migraine medication or triptans within 30 days prior to first dose; any current or lifetime clinical diagnosis of schizophrenia spectrum or other psychotic disorder, bipolar I or II disorder, or borderline personality disorder; clinically significant depression, defined as: any current or lifetime clinical diagnosis of major depressive disorder or other depressive disorder; any history of pharmacological treatment for depression; any current clinical diagnosis of anxiety disorder or any history of pharmacological treatment for anxiety within 1 year prior to screening; or any history of psychiatric hospitalization. Neurological and psychiatric history will be assessed at Screening through clinical interview by the investigator/delegate, supplemented by review of available medical records.
• Clinically significant (as judged by the investigator/delegate) cardiovascular disorders, including history of prolonged QTc interval (defined as QTcF \>450 ms for males or \>470 ms for females, or any clinically significant ECG abnormality); or chronic cardiovascular diseases (specifically including history of cardiac valvulopathy or pulmonary hypertension or hypertension); or current hypertension (resting systolic blood pressure \> 140 mmHg or diastolic blood pressure \>90 mmHg). Blood pressure assessment can be repeated at the discretion of the investigator/delegate.
• Clinically significant (as judged by the investigator/delegate) systemic diseases or conditions, including immunodeficiency or immunosuppressive disorders; malignant neoplastic diseases; or clinically significant endocrine, respiratory, hematologic (including coagulation), or digestive system diseases that may interfere with the safety of the participant or the interpretation of study results.

Sponsors & Collaborators

• NeuShen Therapeutics: lead

Study Sites (1)

CMAX Clinical Research Pty Ltd

Adelaide, South Australia, 5000, Australia

Location

MeSH Terms

Interventions

Paroxetine

Intervention Hierarchy (Ancestors)

Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Central Study Contacts

Jin Lili, MS

CONTACT

+86 13918207440; lili.jin@neushen.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 16, 2026
• First Posted: June 25, 2026
• Study Start: June 1, 2026
• Primary Completion: July 1, 2026
• Study Completion (Estimated): May 1, 2027
• Last Updated: July 30, 2026

Record last verified: 2026-07

Locations

AU (1)